Otitis Media (Ear Nose Throat Disorders) - Drugs in Development, 2021

March 2021 | 92 pages | ID: O1E60DDF62FAEN
Global Markets Direct

Abstracts

Otitis Media (Ear Nose Throat Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Drugs in Development, 2021, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 3, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
• The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Otitis Media - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Otitis Media - Companies Involved in Therapeutics Development
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earnano LLC
Eledon Pharmaceuticals Inc
Furen Pharmaceutical Group Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Laboratorios Salvat SA
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc
Yuhan Corp
Otitis Media - Drug Profiles
(cholesteryl palmitate + colfosceril palmitate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ciprofloxacin hydrochloride + fluocinolone acetonide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dexamethasone + piperacillin + tazobactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMTX-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMTX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTC-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OR-404IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCL-1440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tebipenem pivoxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
V-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAX-24 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAX-XP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1917 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Otitis Media - Dormant Projects
Otitis Media - Product Development Milestones
Featured News & Press Releases
Jan 13, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement update on an investigational ear drug product
Jun 01, 2020: Novus Therapeutics announces topline results of phase 2a clinical trial of OP0201 in acute otitis media
Mar 02, 2020: Novus Therapeutics completes enrollment of Phase 2a trial of OP0201 in pediatric patients with acute otitis media
Jan 13, 2020: Novus Therapeutics provides update on OP0201
Oct 29, 2019: Novus Therapeutics receives FDA guidance on OP0201 phase 2a study in patients with Chronic Otitis Media with Effusion
Jun 10, 2019: Novus Therapeutics to present OP0201 data at the 20th international symposium on recent advances in otitis media
Apr 23, 2019: Novus’ Phase I trials of otitis media drug meet primary objective
Feb 20, 2019: Novus Therapeutics begins dosing in otitis media drug trial
Feb 11, 2019: Novus Therapeutics doses first subjects in phase 1 pharmacodynamics study of OP0201
Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201
Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board
Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201
Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Otitis Media, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Otitis Media - Pipeline by Ceolia Pharma Co Ltd, 2021
Otitis Media - Pipeline by Clarametyx Biosciences Inc, 2021
Otitis Media - Pipeline by Earnano LLC, 2021
Otitis Media - Pipeline by Eledon Pharmaceuticals Inc, 2021
Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd, 2021
Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2021
Otitis Media - Pipeline by Laboratorios Salvat SA, 2021
Otitis Media - Pipeline by Merck & Co Inc, 2021
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2021
Otitis Media - Pipeline by MyX Therapeutics Inc, 2021
Otitis Media - Pipeline by NTC srl, 2021
Otitis Media - Pipeline by O-Ray Pharma Inc, 2021
Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, 2021
Otitis Media - Pipeline by ProclaRx LLC, 2021
Otitis Media - Pipeline by Vaxcyte Inc, 2021
Otitis Media - Pipeline by Vyome Therapeutics Inc, 2021
Otitis Media - Pipeline by Yuhan Corp, 2021
Otitis Media - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Otitis Media, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021